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respectively. MRI-images of tumor recurrences were fused with the original planning-CT, and patterns of failure were deﬁned
according to the location of recurrence respect the isodose lines (IDL). Central recurrences were deﬁned when the recurrence
was located within the 65Gy-IDL, local recurrence in the 55–60Gy-IDL, marginal recurrence in the 30–50Gy-IDL and distal failure
when the recurrence was located outside the 30Gy-IDL.
Results. From January 2007 to May 2012, 48 pats with a MFU of 39.12 months (9–73 months) were enrolled in the study. Twenty-
two pats (44.9%), 2-pats (4.1%), 0-pats (0%), 4-pats (8.2%) and 7-pats (14.3%) had central, local, marginal, central plus local and
distal recurrences, respectively. Local–central control was achieved in 19-pats (42%). Central recurrences were more frequently
observed in pats with unmethylated-MGMT (13/19 pats, 68%). Median OS and PFS were 21 months and 14 months, respectively.
Conclusions. In this series, the patterns of failure in GB were predominantly local–central (50%). Using 11C-MET-PET planning
images and highly conformal dose distribution, we have not observed an increase in marginal recurrences rates. Patients with
unmethylated-MGMT tumors have more local–central recurrences. Future studies with the inclusion of a greater number of pats
are warranted to conﬁrm these data.
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Purpose. To determine, at ﬁrst progression, if patients receiving anti-VEGF show different patterns of relapse compared with
patients treated with conventional concomitant RT/CT.
Methods. Patients fromour center included in a prospective trial designed for neoadjuvant treatment in only biopsied glioblastoma
patients are analyzed. All GD-enhanced T1 and FLAIR MRI sequences were reviewed and co-registered with treatment planning
done just before radiotherapy. Patterns of relapse after radiotherapy were deﬁned as follows: A. all relapses were within the
95% of isodose; B. all relapses were between 95% and 50% of isodose; C. all relapses were outside 50% of isodose. Two groups of
patients were included; those treated with temozolamide (TMZ) alone (TMZ group) before radiotherapy and those who received
neoadjuvant TMZ and Bevacizumab (BV) (TMZ+BV group).
Results. Nineteen patients are included at ﬁrst analysis. Thirteen had progressed after complete radiation (RDT) treatment and
were available for evaluation (4 in TMZ group and 9 in TMZ+BV group). Mean time to progression after RDT was 150 days in
TMZ-group and 151.8 days in TMZ+BV group. GD-enhanced T1 did not show differences in patterns of relapse between both
groups, being the pattern A the most common (100% in TZM group vs 88.8% in TMZ+BZM group). However, FLAIR sequence
showed more B and C patterns in both groups. A–C patterns were observed in 25%, 75% and 0% in TMZ group; and 33.3% for each
pattern in TMZ+BV group. Results showed a trend to detect more C patterns of relapse in patients who had received anti-VEGF
treatment.
Conclusions. These results show that FLAIR sequence is essential in deﬁning the patterns of relapse in patients treated with
neoadjuvant treatment. Sample will be updated at presentation. Deﬁning patterns of relapse with new drugs could be deﬁnitive
for radiotherapy volumes and doses.
http://dx.doi.org/10.1016/j.rpor.2013.03.141
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Introduction. Anaplastic oligodendroglioma is a malignant brain tumor uniquely sensitive to treatment with both chemotherapy
and radiotherapy. There are few prospective clinical trials for newly diagnosed patients and multiple approaches to the treatment
of these patients. This review is an analysis of our patients with anaplastic oligodendroglioma and oligoastrocytoma.
Material and methods. We have reviewed the treatment results in 12 patients, ten with intracranial anaplastic oligodendroglioma
and two with anaplastic oligoastrocytoma, treated from 2007 through 2012 at the Hospital General de Ciudad Real. Ten patients
received adjuvant radiotherapy with median dose of 60Gy and concomitant Temozolamide and two treated with RTOG BR0103
scheme. The median age was 45 years old. Eleven patients had determined the co-delection 1p19q, 2 of them had a negative 1p,
one had negative 1p19q and the rest, had a co-deletion.
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Results. The overall survival rates were 100% and 92% at 2 and 5 years, respectively. Five of patients (41.6%) had history of
oligodendrogliomaGII and themedian time to progressionwas 3.5 years. These patients belong to the 55.5% of patients diagnosed
with a GII in this period of time. Two of them, had presented third relapse with median progression-free survival of 2 years. Only
one patient had relapse with primary anaplastic oligodendroglioma with median time to tumor progression of 8 months and
died in 2 years with fotemustine and avastin. This patient had 1p negative.
Conclusion. Based on WHO classiﬁcation and prognostic factor, our combined treatment modality consisting of surgery,
postoperative high-dose RT and chemotherapy based in Temozolamide for patients with anaplastic oligodendroglioma and
oligoastrocytoma was effective. We should ask about other therapeutic strategy in patients with oligodendroglioma GII. We
could think that patients with negative co-deletion higher risk of recurrence. Further studies are needed with more patients and
longer follow-up to verify these results.
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Background. Treatment approach in meduloblastoma (MB) has changed through the years. The purpose of this study is to assess
the prognostic factors for survival of craniospinal irradiation (CSI) with different modalities of radiotherapy (RT) in MB patients.
Materials and methods. The studywas conducted for patientswithprimaryMB treatedwithCSI fromAugust 1996 throughMay2012.
Inclusion criteria included no prior history of RT and minimum follow up of 6 months for alive patients. Thirty-four patients
(standard risk, N=21; high risk, N=13) met such criteria. Median CSI dose was 36Gy in 20 fractions. The tumor bed received
50–60Gy at 1.5–2Gy/fraction. RT technique used was two dimensional RT (N=11), three dimensional RT (N=15), volumetric
modulated arc therapy (VMAT; N=3), and tomotherapy (N=5). Toxicity was scored using the Radiation Therapy Oncology Group
(RTOG) scoring system. Univariate and multivariate analyses were performed to deﬁne predictors for survival.
Results. The median age at diagnosis was 8 years (range, 2–43) and the median follow-up for alive patients (N=20) 56 months
(range, 9–198). Two and three-year overall survival was 74% and 65%, respectively. Twenty patients underwent complete surgical
resection whereas 14 underwent partial resection. Eleven patients received postoperative chemotherapy (CT). Nine patients had
grade ≥3 hematological toxicity. Overall, 14 patients died. In the univariate analysis, leptomeningeal and cerebrospinal ﬂuid
spread at diagnosis, high risk stage, partial surgery, and CT before RT associated with higher risk of mortality (p<0.05). In the
multivariate analysis, only cerebrospinal ﬂuid spread at diagnosis maintained signiﬁcance (p=0.004).
Conclusion. Several factors related to high risk MB patients, particularly cerebrospinal ﬂuid spread at diagnosis, are associated
with a higher risk of mortality. Further research is necessary to assess a better treatment approach in high risk MB patients in
order to improve the outcome.
http://dx.doi.org/10.1016/j.rpor.2013.03.143
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Objectives. Treatment of high grade gliomas (HGG) have consisted in maximum surgical resection followed by RT concomitant
with temozolomide (TMZ) followed by TMZ for six cycles. This retrospective study evaluates survival for patients with HGG
treated in our institution.
Materials and methods. Data was collected from patient case notes. Statistical analysis was carried out using SPSS package.
Results. Between January 2003 and June 2012, 119 patients with HGG were treated with. They received best supportive care if they
had poor performance status. Histologically, 92% were GM, 4% AA, 4% AOA and 1% negative biopsy. Demographic data were as
follows: 67 males (56%) and 52 females (44%). Median age was 67 years (range 24–91). 4% of the patients had no biopsy because
age was over 80 years old or central tumor location. 86% of the patients had undergone debulking surgery, whereas in 10% just
biopsy was performed. 81 (68%) patients received RT with median dose was 60Gy (range 12–66). Of whom, 88% completed RT. 52
(44%) patients received concurrent radiochemotherapy and 42 (35%) adjuvant TMZ. The major causes to do not receive adjuvant
RT-TMZ were biopsy procedure only or poor performance status (32% of the patients). Median follow-up time was 8 months
